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Objective: Tumor necrosis factor is an important mediator of lung transplant
ischemia-reperfusion injury, and soluble type I tumor necrosis factor receptor binds
to tumor necrosis factor and works as a tumor necrosis factor inhibitor. The
objectives of this study were to demonstrate that gene transfer of type I tumor
necrosis factor receptor–IgG fusion protein reduces lung isograft ischemia-reperfu-
sion injury and to compare donor endobronchial versus recipient intramuscular
transfection strategies.
Methods: Three donor groups of Fischer rats (n  6/group) underwent endobron-
chial transfection with either saline, 2  107 plaque-forming units of control
adenovirus encoding -galactosidase, or 2  107 plaque-forming units of adenovi-
rus encoding type I tumor necrosis factor receptor–IgG fusion protein. Left lungs
were harvested 24 hours later. Two recipient groups (n  6/group) underwent
intramuscular transfection with 2  107 plaque-forming units or 1  1010 plaque-
forming units of adenovirus encoding type I tumor necrosis factor receptor–IgG
fusion protein 24 hours before transplantation. All donor lung grafts were stored for
18 hours before orthotopic lung transplantation. Graft function was assessed 24
hours after reperfusion. Transgene expression was evaluated by means of enzyme-
linked immunosorbent assay and immunohistochemistry of type I tumor necrosis
factor receptor.
Results: Endobronchial transfection of donor lung grafts with 2  107 plaque-
forming units of adenovirus encoding type I tumor necrosis factor receptor–IgG
fusion protein significantly improved arterial oxygenation compared with the saline
and -galactosidase donor groups (366.6  137.9 vs 138.8  159.9 and 140.6 
131.4 mm Hg, P  .009 and .010, respectively). Recipient intramuscular transfec-
tion with 1  1010 plaque-forming units of adenovirus encoding type I tumor
necrosis factor receptor–IgG fusion protein improved lung graft oxygenation com-
pared with that seen in the low-dose intramuscular group (2  107; 320.3  188.6
vs 143.6  20.2 mm Hg, P  .038). Type I tumor necrosis factor receptor–IgG
fusion protein was expressed in endobronchial transfected grafts. In addition,
intramuscular type I tumor necrosis factor receptor–IgG fusion protein expression
was dose dependent.
Conclusions: Donor endobronchial and recipient intramuscular adenovirus-medi-
ated gene transfer of type I tumor necrosis factor receptor–IgG fusion protein
improved experimental lung graft oxygenation after prolonged ischemia. However,
donor endobronchial transfection required 500-fold less vector. Furthermore, at low
vector doses, it does not create significant graft inflammation.
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Lung transplantation is an accepted treatmentfor end-stage lung disease.1 Unfortunately,ischemia-reperfusion injury and rejectioncontinue to result in graft dysfunction. Al-though numerous studies have been per-formed to reduce these complications, defin-
itive treatments have not been established.2 Gene therapy
has the potential to improve clinical lung transplantation.3
Recently, our laboratory and others have demonstrated that
gene transfer is feasible and improves outcome in an exper-
imental model of lung transplantation.4,5
Tumor necrosis factor (TNF) is a proinflammatory cyto-
kine that mediates a variety of pathologic conditions.6 It is
mainly produced by macrophages and contributes to a va-
riety of inflammatory injuries, including ischemia-reperfu-
sion injury.7 Soluble type I TNF receptor (sTNF-RI) is a
receptor for TNF- and TNF-. It has been identified in
serum and urine.8 sTNF-RI binds to TNF- and TNF- and
inhibits their function.9 Therefore gene transfer of sTNF-
RI-IgG fusion protein has the potential to inhibit the inflam-
matory cascade meditated by TNF and to reduce acute lung
graft injury.
Several strategies have been considered for use of gene
therapy in lung transplantation. These include the type of
vector (eg, naked plasmid, liposome, or adenovirus), ex
vivo versus in vivo gene transfer, delivery to the donor or
recipient, and systemic versus local delivery strategies. En-
dobronchial gene transfer to the donor lung graft is an
excellent localized strategy for the treatment of transplant-
related injuries, such as ischemia-reperfusion injury and
graft rejection. Endobronchial gene transfer of human IL-10
ameliorates lung graft ischemia-reperfusion injury,10 and
endobronchial transfection of naked transforming growth
factor 1 cDNA attenuates acute lung rejection.11 Intramus-
cular gene therapy to the recipient releases transgene protein
into the systemic circulation and has also ameliorated ex-
perimental lung transplant injury. Recipient intramuscular
gene transfer of active transforming growth factor 1 atten-
uates acute lung rejection.12 Recipient intramuscular gene
transfer of interleukin 10 reduces neutrophil sequestration
and emigration in lung isografts.13 No studies to date have
compared the efficacy of endobronchial transfection with
intramuscular transfection in reducing acute lung injury.
The aims of this study were to determine whether adenovi-
rus-mediated gene transfer of sTNF-RI-IgG fusion protein
decreases lung graft ischemia-reperfusion injury and to
compare the efficacy of donor endobronchial transfection
with that of recipient intramuscular transfection.
Materials and Methods
Animals
Fischer 344 rats (Harlan Sprague Dawley Inc, Indianapolis, Ind),
weighing 250 to 280 g, were used in all experiments. The Animal
Studies Committee at Washington University approved all animal
procedures. Animals received humane care in compliance with the
“Guide for the Care and Use of Laboratory Animals” prepared by
the National Academy of Sciences and published by the National
Institutes of Health (National Institutes of Health publication no.
85-23, revised 1985).
Adenoviral Vectors
Adenovirus encoding sTNF-RI-Ig (Ad.sTNF-RI-Ig) originates
from a replication-deficient recombinant type 5 adenovirus lacking
the E1 and E3 loci.14 sTNF-RI-Ig cDNA was inserted in place of
the E1 region, and expression was driven by the cytomegalovirus
promoter. Ad.sTNF-RI-Ig encodes a fusion protein consisting of
the extracellular domain of the human 55-kd TNF- receptor and
the CH2 through CH3 domains of a mouse IgG1 heavy chain.15
The adenovirus used in this study was provided as a gift from Dr
Paul D. Robbins, Departments of Molecular Genetics and Bio-
chemistry, University of Pittsburgh, Pittsburgh, Pa.16
The first-generation, replication-deficient, adenovirus serotype
5 carries the Escherichia coli LacZ gene (Ad.LacZ). It is driven by
the constitutive cytomegalovirus promoter and encodes the en-
zyme -galactosidase (-gal). -gal is a nonfunctional reporter
gene used as an adenovirus control (University of North Carolina,
Chapel Hill, NC).
Purified viral aliquots were stored at 70°C in 10% glycerol
buffered with 10 mmol/L Tris, 140 mmol/L NaCl, and 1 mmol/L
MgCl2. These stocks were thawed and diluted in sterile normal
saline solution immediately before use.
Experimental Design
Two experiments were performed in this study. Experiment 1
determined the transgene expression of sTNF-RI-Ig immediately
before transplantation. Experiment 2 evaluated the effect of sTNF-
RI-Ig gene transfection on lung graft ischemia-reperfusion injury.
Both experiments had the same study groups. Fischer 344 rats
were divided into 5 groups. Three donor groups underwent endo-
bronchial transfection with either saline (endobronchial saline), 2
 107 plaque-forming units (pfu) of adenovirus control encoding
-gal (Ad.LacZ; endobronchial -gal), or 2  107 pfu of adeno-
virus encoding sTNF-RI-Ig (Ad.sTNF-RI-Ig; endobronchial
sTNF-RI). Two recipient groups underwent intramuscular trans-
fection with either 2  107 pfu Ad.sTNF-RI-Ig (low-dose intra-
muscular group) or 1  1010 pfu Ad.sTNF-RI-Ig (high-dose in-
tramuscular group; Figure 1).
ENDOBRONCHIAL GENE TRANSFECTION OF THE DONOR. Ani-
mals were anesthetized with subcutaneous injection of ket-
amine chloride (25 mg/kg) and atropine sulfate (0.25 mg/
kg). After endotracheal intubation with a 14-gauge catheter,
animals were mechanically ventilated with a Harvard ven-
tilator (tidal volume, 2.5 mL; respiratory rate, 60 breaths/
min). Donors underwent right thoracotomy, and the carina
was dissected. A catheter was introduced through the endo-
tracheal tube into the left main bronchus, and vector diluted
in 0.1 mL of sterile normal saline solution was instilled.
After 10 minutes of bilateral ventilation, the left main bron-
chus was clamped for 60 minutes at end-inspiratory volume.
The thoracotomy was closed after removing the bronchial
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clamp. A temporary chest tube was placed, and the animal
was recovered and extubated.
DONOR LUNG PROCUREMENT. Donor rats were anesthe-
tized with intraperitoneal pentobarbital (65 mg/kg), me-
chanically ventilated, and heparinized (300 units), and a
median laparosternotomy was performed. Lungs were
flushed through the main pulmonary artery with 20 mL of
cold (4°C) low potassium dextran glucose solution at 20 cm
H2O pressure. The heart-lung block was removed with the
lungs inflated at end-inspiratory volume. The left lung was
isolated and stored at 4°C for 18 hours before implantation.
RECIPIENT INTRAMUSCULAR GENE TRANSFER. Animals were
anesthetized with halothane, and vector dissolved in 1 mL
of saline was injected into the right gastrocnemius muscle.
Animals were recovered and transplanted 24 hours later.
Experiment 1: sTNF-RI-Ig Expression Before
Transplantation
In all 3 donor endobronchial groups (n  3/group), donor lung
grafts were harvested 24 hours after transfection, and sTNF-RI-Ig
transgene expression was measured by using an sTNF-RI enzyme-
linked immunosorbent assay (ELISA). Immunohistochemistry of
sTNF-RI was performed to document epithelial cell transgene
expression. In addition, for the endobronchial sTNF-RI group, we
measured transgene expression in donor lung grafts after 18 hours
of cold preservation and in the nontreated donor right lung at the
time of harvest.
In both recipient intramuscular groups (n  3/group), sTNF-
RI-Ig transgene expression in serum and in the right gastrocnemius
muscle was evaluated 24 hours after gene transfection by using
sTNF-RI ELISA.
STNF-RI ELISA. Lung and muscle samples were ho-
mogenized with a lysis solution consisting of 100 mmol/L
potassium phosphate dibasic, pH 7.8, including 0.2% Triton
X-100 (Fisher Scientific, Fair Lawn, NJ), 5 g/mL Pepsta-
tin A (Boehringer-Mannheim, Indianapolis, Ind), and the
protease inhibitor Complete Mini (Roche, Inc, Nutley, NJ).
After 15 minutes at room temperature, the extraction was
centrifuged at 11,000g for 10 minutes at 4°C. Serum sam-
ples were obtained by means of centrifugation of arterial
blood samples at 1,000g for 10 minutes at 4°C. A human
sTNF-RI ELISA kit was used (R&D Systems Inc, Minne-
apolis, Minn). There is no cross-reactivity between the
human and rat sTNF-RI proteins. Optical density was de-
termined by using an Ultra Microplate Reader (EL808;
Bio-Tek Instruments, Inc, Winooski, Vt) set to 450 nm.
Total soluble protein (in picograms per milligram of total
protein) was determined by using the method of Pierce
Laboratories (Rockford, Ill).17
IMMUNOHISTOCHEMISTRY OF STNF-RI. Tyramide Signal
Amplification Biotin System kits (NEN Life Science Prod-
ucts, Inc, Boston, Mass) were used for immunohistochem-
istry. Briefly, lungs were perfused with 20 mL of normal
saline and 20 mL of HistoChoice (Amresco, Solon, Ohio).
Specimens were fixed, cut, mounted, deparaffinized, and
then treated with Dako Target Retrieval Solution (Dako,
Carpinteria, Calif). Sections were incubated for 60 minutes
with an FcII receptor blocker (BD PharMingen, San Di-
ego, Calif) and with Super Block Blocking Buffer (Pierce
Chemical Co). Sections were then incubated overnight with
a biotinylated goat anti-human sTNF-RI polyclonal anti-
body (BD PharMingen) at 1:20 dilution in TNB Blocking
Buffer at 4°C. Next, slides were incubated with Streptavi-
din-Alkaline Phosphatase (NEN Life Science Products,
Inc). Specific binding was detected by using the BCIP/NBT
substrate working solution (Vector Laboratories, Inc, Bur-
lingame, Calif) containing 5 mmol/L levamisole (Vector
Laboratories, Inc). Slides were then counterstained with
Figure 1. Experimental protocol. The experimental protocol was separated by the delivery route and vector dose.
Three donor groups received endobronchial transfection into the lung graft before harvest (Donor Graft Endobron-
chial Delivery) and 2 recipient groups received intramuscular transfection before transplantation (Recipient
Intramuscular Delivery).
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nuclear fast red, dehydrated, and mounted, and cover slips
were placed.
Experiment 2: The effect of sTNF-RI-Ig gene
transfection on lung graft ischemia-reperfusion injury
In the 3 donor endobronchial groups (n  6/group), donor lung
grafts were harvested 24 hours after transfection. In both recipient
intramuscular groups (n 6/group), orthotopic left lung transplan-
tation was performed 24 hours after gene transfection. All donor
lungs were flushed and stored in low potassium dextran glucose
solution for 18 hours at 4°C before transplantation.
Recipient animals were anesthetized and intubated with a 14-
gauge catheter, and a left thoracotomy was performed. The pul-
monary vessels and bronchus were dissected, and the lung graft
was anastomosed by using the modified cuff technique.18
Twenty-four hours after reperfusion, recipient animals were
reanesthetized with pentobarbital. Animals were mechanically
ventilated through a tracheostomy with 100% oxygen. The right
main bronchus and pulmonary artery were clamped to isolate the
left lung graft. Animals were ventilated for 5 minutes at a tidal
volume of 1.5 mL, a respiratory rate of 100 breaths/min, and a
peak end-expiratory pressure of 1.0 cm H2O. An arterial blood gas
analysis was performed, and the lungs were flushed with 20 mL of
4°C saline solution. Left lung grafts were divided into 3 sections:
the upper third was used for ELISA of sTNF-RI and rat TNF-
after reperfusion, the middle third was used for myeloperoxidase
(MPO) activity measurement, and the lower third was weighed,
dried at 80°C for 48 hours, and then reweighed for calculation of
the wet/dry weight ratio. Serum from all groups and transfected
right gastrocnemius muscles from both recipient intramuscular
groups was used for ELISA of sTNF-RI.
MPO ACTIVITY. Quantitative MPO activity was deter-
mined as previously described.19 One unit of enzyme activ-
ity was defined as 1.0 optical density units per minute per
milligram of tissue protein at room temperature.
ELISA OF RAT TNF-. Reperfused lung grafts from all
5 groups were used for ELISA of endogenous rat TNF-, as
described earlier for sTNF-RI. The rat TNF- ELISA kit
was purchased from R&D Systems, Inc.
Statistical analysis
All values are described as means  SD. Data not normally
distributed were analyzed after logarithmic correction. One-way
analysis of variance with pairwise comparison by using the Fisher
least significant difference was used to compare the differences
among multiple groups.
Results
Experiment 1
ELISA OF STNF-RI AFTER STNF-RI-IG GENE TRANSFER.
Significant transgene expression of sTNF-RI-Ig was de-
tected in left lungs from the endobronchial sTNF-RI
group but not from the other endobronchial groups. In
addition, there was no sTNF-RI-Ig expression detected in
the rights lungs of the endobronchial sTNF-RI group (Fig-
ure 2). In the recipient intramuscular groups, serum and
muscle sTNF-RI-Ig transgene expression was dose depen-
dent (Figure 3).
IMMUNOHISTOCHEMISTRY OF STNF-RI IN THE LUNG. Posi-
tive immunohistochemical staining for sTNF-RI was ob-
served in Ad.sTNF-RI-Ig endobronchially transfected
lungs. The distribution of expression was increased in the
hilar bronchus compared with the alveoli in the peripheral
lung (Figure 4, A). Staining was detected in epithelial cells
Figure 2. Lung graft expression of sTNF-RI-Ig after endobronchial
transfection. Twenty-four hours after endobronchial transfection,
sTNF-RI-Ig expression was significantly higher in the endobron-
chial (EB) sTNF-RI group. This expression was specific to the
transfected left lung, and there was no expression in the un-
treated right lung. In addition, sTNF-RI-Ig expression is main-
tained during prolonged, 18-hour, cold ischemia. Isografts in the
other endobronchial groups showed no significant gene expres-
sion.
Figure 3. Serum and muscle expression of sTNF-RI-Ig after intra-
muscular transfection of Ad.sTNF-RI-Ig. The muscle and serum
sTNF-RI-Ig expression was almost 200-fold greater in the high-
dose intramuscular (IM) group (1 1010 pfu) than in the low-dose
intramuscular group (2  107 pfu).
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of the bronchi and alveolar cells but was not detected in
endothelial, smooth muscle, or interstitial tissue cells (Fig-
ure 4, B). As expected, no sTNF-RI staining was present in
lungs transfected with -gal or saline solution because these
vectors do not contain the human gene encoding sTNF-RI.
DEGREE OF NEUTROPHIL INFILTRATION INTO LUNG GRAFTS
AFTER AD.STNF-RI-IG TRANSFECTION. The MPO activity in
lung tissue 24 hours after endobronchial transfection was
quantified to measure the effect of this adenovirus-mediated
transfection strategy on neutrophil infiltration (a reflection
of inflammation). There was no significant difference in
MPO between grafts transfected with Ad.sTNF-RI-Ig and
untreated control grafts (0.099  0.047 vs 0.076  0.020
OD · min1 · mg1 protein, P  .286).
Experiment 2
ISOLATED LUNG ISOGRAFT GAS EXCHANGE. Endobronchial
transfection of 2  107 pfu of Ad.sTNF-RI-Ig (endobron-
chial sTNF-RI) significantly improved PaO2 levels com-
pared with those in the control endobronchial groups. Im-
portantly, the PaO2 for the endobronchial sTNF-RI group
was significantly higher than that for the low-dose intramus-
cular group treated with the same dose of 2  107 pfu of
Ad.sTNF-RI-Ig (Figure 5). There were no significant dif-
ferences in the mean carbon dioxide levels between the
groups (P  .122).
WET/DRY WEIGHT RATIO. The wet/dry weight ratio is an
indicator of tissue edema. The endobronchial sTNF-RI
group and the high-dose intramuscular group had a trend
toward lower wet/dry ratios, reflecting less tissue edema,
than the other groups (6.15  0.57 and 6.46  0.73 vs 6.56
 0.87, 7.06  1.97, and 7.29  0.69, respectively; P 
.083).
MPO ACTIVITY AFTER LUNG GRAFT REPERFUSION. MPO
activity 24 hours after reperfusion is a reflection of neutro-
phil infiltration into lung grafts.19 Lung graft MPO levels
were reduced in the endobronchial sTNF-RI group com-
pared with in the endobronchial saline group (0.106 
0.045 vs 0.298  0.142 OD · min1 · mg1 protein, P 
.004). There were no significant differences between the
other groups (P  .059) The values were 0.323  0.478 in
Figure 4. Immunohistochemistry of human sTNF-RI in rat lungs after endobronchial transfection of Ad.sTNF-RI-Ig.
Heterogeneous staining was observed in alveoli (A, original magnification 40). Epithelial cells of the bronchus,
bronchioles, and alveoli show sTNF-RI staining, but endothelial, smooth muscle, and interstitial cells do not (B,
original magnification 100).
Figure 5. Isolated lung graft oxygenation 24 hours after reperfu-
sion. Twenty-four hours after reperfusion, the right hilum was
clamped, and the left lung was ventilated with 100% oxygen for
5 minutes. The endobronchial (EB) sTNF-RI group had superior
arterial oxygenation (PaO2) compared with the control endobron-
chial groups and the low-dose intramuscular (IM) group (receiv-
ing the same vector dose of 2  107 pfu, P < .011). The high-dose
intramuscular group (1  1010 pfu) had a similar improvement in
PaO2 to that seen in the endobronchial sTNF-RI group but required
500 times more vector.
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the endobronchial -gal group, 0.171  0.056 in the low-
dose intramuscular group, and 0.156  0.037 in the high-
dose intramuscular group (in  optical density units per
minute per milligram).
ELISA OF STNF-RI. The extracts derived from muscle,
lung, and serum 24 hours after reperfusion were used for the
measurement of sTNF-RI. Transgene expression of sTNF-
RI-Ig in the muscles and serum samples of the intramuscu-
lar groups was dose dependent. sTNF-RI in muscle was 8.3
 6.2 pg/mg protein in the low-dose intramuscular group
and 4586.7  834.3 pg/mg protein in the high-dose intra-
muscular group. sTNF-RI in serum was 1.3  1.5 pg/mg
protein in the low-dose intramuscular group and 1029.8 
302.5 pg/mg protein in the high-dose intramuscular group.
The lung grafts of the endobronchial sTNF-RI group ex-
pressed large amounts of sTNF-RI-Ig during reperfusion. A
small amount of sTNF-RI-Ig was also detected in lung
grafts of the high-dose intramuscular group 24 hours after
reperfusion (Figure 6).
ELISA OF RAT TNF-. The endogenous rat TNF- lev-
els in reperfused lung grafts were measured to determine the
effect of sTNF-RI-Ig transfection on the production of this
proinflammatory cytokine. The endogenous TNF- levels
were significantly lower in the endobronchial sTNF-RI
group than in the endobronchial saline group (2.39  1.46
vs 10.15  9.94 pg/mg protein, P  .013) but not signifi-
cantly different than in the other groups. The values of the
endobronchial -gal, low-dose intramuscular, and high-
dose intramuscular groups were as follows: 6.79  4.86,
4.63  1.53, and 3.01  0.86 pg/mg protein (P  .144,
.450, and .832, respectively).
Discussion
Ischemia-reperfusion injury is inevitable during lung trans-
plantation and is the most important predictor of early
postoperative morbidity and mortality.20 Severe graft dys-
function prolongs the length of stay in the intensive care
unit and might require extracorporeal membrane oxygen-
ation.21,22 The pathophysiology of this acute lung injury is
complex. One important factor that influences the degree of
ischemia-reperfusion injury is the release of proinflamma-
tory cytokines.23
TNF is an important proinflammatory cytokine that reg-
ulates many biologic functions, including normal host re-
sistance to infection, malignant tumor growth, and the in-
duction of the inflammatory response.6 TNF also plays a
crucial role in inducing lung transplantation ischemia-reper-
fusion injury.23 Two kinds of TNF receptors have been
identified, type I (p55) and type II (p75), that specifically
bind TNF with equal affinity.24 These soluble receptors are
capable of neutralizing and modulating the biologic activity
of TNF.8 This study evaluated the ability of adenovirus-
mediated gene transfer of sTNF-RI-Ig to inhibit TNF and
reduce acute lung injury. Previous studies from our labora-
tory and others have demonstrated the feasibility of gene
therapy in the field of lung transplantation.4,5 We have used
several delivery strategies to reduce ischemia-reperfusion
injury, including the intravenous,25 intramuscular,13 and
endobronchial10 routes. However, the amount of vector and
the efficacy of these delivery routes had not been compared.
In the present study both endobronchial transfection (2
107 pfu) of the donor and high-dose (1  1010 pfu) intra-
muscular transfection of the recipient with Ad.sTNF-RI-Ig
improved lung graft oxygenation. Adenovirus-mediated
gene transfer of sTNF-RI-Ig produces sTNF-RI protein,
which inhibits the proinflammatory effects of TNF. In ad-
dition, endobronchial Ad.sTNF-RI-Ig transfection reduced
neutrophil infiltration into lung grafts and reduced the ex-
pression of endogenous rat TNF- 24 hours after reperfu-
sion. In the intramuscular transfection groups neutrophil
sequestration and endogenous rat TNF- expression was
lower than in the endobronchial control groups but not
significantly different from each other.
The lung ELISA data for sTNF-RI provides a probable
explanation for these results. The endobronchial Ad.sTNF-
RI-Ig and high-dose intramuscular recipient groups both
have transgene expression in the lung 24 hours after lung
graft reperfusion. However, the endobronchial Ad.sTNF-
RI-Ig group had 50-fold higher gene expression than the
high-dose intramuscular recipient group. Therefore the en-
dobronchial transfected group has a much higher amount of
sTNF-RI-Ig in the lung graft to inhibit the function of TNF
strongly and to improve lung graft function.
The donor endobronchial dose of 2  107 pfu and the
recipient intramuscular dose of 1  1010 pfu have been
Figure 6. Lung graft expression of sTNF-RI-Ig after reperfusion.
Twenty-four hours after lung graft reperfusion, sTNF-RI-Ig expres-
sion in the lung graft was significantly higher in the endobron-
chial (EB) sTNF-RI group than in the recipient intramuscular (IM)
groups or the control endobronchial groups (P < .004).
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examined in previous reports.10,13 Endobronchial transfec-
tion with 2  106 pfu did not improve lung graft oxygen-
ation, and greater than 1  108 pfu produced macroscopic
lung edema, atelectasis, and inflammation.10 In addition, the
relatively low adenoviral vector dose of 2  107 pfu has
been shown to result in minimal epithelial inflammation.10
Immunohistochemistry in the endobronchially transfected
lungs showed heterogeneous and patchy staining of
sTNF-RI in epithelial cells. Because the majority of isch-
emia-reperfusion injury occurs in endothelial cells, endo-
bronchial gene transfer might work in a paracrine manner.10
A potential side effect of endobronchial transfection is local
inflammation. However, this protocol uses low-dose adeno-
virus gene transfer to limit this complication. Furthermore,
MPO activity, a reflection of neutrophil infiltration, is not
increased in Ad.sTNF-RI-Ig–treated lungs.
The low-dose intramuscular recipient group received the
same amount of vector (2  107 pfu) as the endobronchial
Ad.sTNF-RI-Ig group but did not have improved lung graft
function. In fact, an intramuscular dose of 1 1010 pfu, 500
times more vector, was required to achieve similar results.
These data demonstrate that intramuscular gene delivery
requires significantly more vector than a targeted endobron-
chial delivery strategy. The use of less adenoviral vector
decreases costs, reduces local inflammation, and reduces the
cellular and humoral immune response.26 Furthermore, Our
laboratory has recently demonstrated that endobronchial
gene transfer is indeed very selective. Endobronchial deliv-
ery of adenovirus-mediated -gal produced excellent -gal
expression in the lung and negligible expression in the
serum, muscle, liver, kidney, heart, and spleen.27
After intramuscular gene delivery, myocytes produce the
transgene and release it into the systemic circulation to work
in an endocrine manner.28 Although it requires more vector
than an endobronchial approach and exposes the systemic
circulation to the adenovirus vector, it might serve a role in
improving lung transplantation.12,13,29 The merits of intra-
muscular transfection are the ease of administration and the
benefit of not introducing adenoviral vector directly into the
lung graft. In addition, it would be relatively easy to treat
the transplant recipient at one’s own institution as soon as a
donor organ is identified.
The main limitation of this study is that gene transfer was
performed 24 hours before lung harvest (endobronchial
groups) and transplantation (intramuscular groups). Be-
cause reperfusion injury begins immediately, gene expres-
sion is required at the time of reperfusion to reduce acute
lung injury. By using current vector technology, 24 hours is
needed for adequate transgene expression.
In conclusion, adenovirus-mediated gene transfer of
sTNF-RI-Ig produces sTNF-RI protein, inhibits TNF, and
ameliorates experimental ischemia-reperfusion injury.
sTNF-RI-Ig gene transfer improves lung graft oxygenation
when delivered endobronchially to donor lung grafts and by
intramuscular transfection to transplant recipients. How-
ever, endobronchial transfection is significantly more effi-
cient, requiring 500-fold less vector than intramuscular gene
transfer. Furthermore, at low vector doses it does not create
significant graft inflammation. It is a selective transfection
strategy that limits systemic vector exposure and warrants
further investigation.
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